A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

NCT03916042 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye

Interventions

DRUG: Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID
DRUG: Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID

Sponsor

Aldeyra Therapeutics, Inc.